Partnership on Deconvolution Software for Organic Compound Identification
News Sep 13, 2005
Shimadzu Scientific Instruments,Inc., has announced that it has entered into a partnership with Ion Signature Technology,Inc.(IST).
This relationship will provide Shimadzu's GC/MS users with the benefits of IST's mass spectrometry software, IST for GC/MS.
IST is designed for high-throughput testing labs that perform GCMS analyses in the areas of environmental science, forensics, petrochemicals, and chemicals.
According to Ion, IST for GC/MS employs a powerful set of algorithms created for ultra-fast, high-sensitivity compound identification and quantification, even in contaminated samples.
Through this partnership, the software will interface with workstation software for Shimadzu’s innovative line of GC/MS instruments, helping labs to accelerate productivity and increase measurement sensitivity by untangling complex data.
"Speed - without sacrificing accuracy - is the order of the day for most testing labs, as they are under tremendous pressure to lower detection limits and increase sample throughput rates," stated John Moore, Ph.D., President and CEO of Ion Signature Technology.
"Through our new partnership with Shimadzu and its high speed, high sensitivity instruments, labs will be able to run analyses considerably faster, yet quickly and efficiently identify complex compounds even in the presence of co-eluting peaks, with full confidence in the accuracy of their QC data."
"This partnership with IST allows Shimadzu to offer enhanced analytical solutions to our customers," stated Bob Clifford, GC/MS Marketing Manager.
"The speed and sensitivity of the Shimadzu GC/MS instruments, now coupled with the matrix isolation improvements from the IST deconvolution software,provides the most complete analytical solution on the market today.”
“Both companies are committed to superior technology and this partnership provides our customers unparalleled performance from a unique hardware/software platform, thus satisfying the needs of both high throughput labs as well as those analyzing complex matrices."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE